Kromek Group PLC Kromek CZT technology to improve cancer surgery
October 14 2020 - 2:00AM
RNS Non-Regulatory
TIDMKMK
Kromek Group PLC
14 October 2020
This is an RNS Reach announcement and the information contained
is not considered to be material or to have a significant impact on
management's expectations of the Group's performance. RNS Reach is
an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
14 October 2020
Kromek Group plc
("Kromek" or the "Group")
Kromek's CZT-based detectors to be used to improve patient
outcomes from cancer surgery
New R&D project with Adaptix Ltd and the University of
Manchester to enhance pathological medical imaging techniques used
during cancer surgery
Kromek (AIM: KMK), a worldwide supplier of detection technology
focusing on the medical, security screening and nuclear markets, is
pleased to announce that it has commenced development of a new
system to improve the pathological medical imaging techniques used
during cancer surgery to distinguish between healthy and
non-healthy tissue - a new application area for Kromek's
technology. The three-year project, which has received grant
funding from Innovate UK, is being conducted in partnership with
Adaptix Ltd, the developer of a Flat Panel X-ray Source (FPS), and
the University of Manchester.
When a cancerous tumour is excised, the surgeon also removes
some tissue around the edge of the tumour (the 'margins') to be
sure that all the cancer has been removed and is not able to
spread. These margins are checked for cancerous tissue while
surgery is ongoing using 'pathology cabinets' that provide 2D or 3D
images.
The project is to develop a prototype of a new type of pathology
cabinet, based on Kromek's CZT detectors and Adaptix's FPS, to
produce high-resolution 3D images that provide more accurate
differentiation of the boundaries between diseased and healthy
tissue. This will enable surgeons to confidently remove the minimum
amount of healthy tissue whilst reducing the risk of more than one
operation being needed and of cancer spreading from diseased tissue
being left after initial surgery. The new system will also be
designed to be cost effective and have a small footprint for ease
of use in an operating theatre.
Kromek's CZT detectors are already incorporated into medical
devices used for early detection of diseases such as breast cancer,
cardiac conditions and osteoporosis.
Dr Arnab Basu, CEO of Kromek, said: "This is an exciting project
for Kromek as it takes our CZT-based detectors into a new
application area. Our technology is already being used by leading
OEMs to enable the early diagnosis of cancer. With this system, we
will contribute to improving the outcome of surgeries through
greater image quality. It will reduce the risk of diseased tissue
remaining and further surgeries being required while minimising the
removal of healthy tissue, which will be of great benefit to both
healthcare providers and patients. We look forward to working
alongside our partners, Adaptix and the University of Manchester,
to complete the development of this new system and take it to the
next stage."
For further information, please contact:
Kromek Group plc
Arnab Basu, CEO
Derek Bulmer, CFO +44 (0)1740 626 060
Luther Pendragon (PR)
Harry Chathli
Claire Norbury
Alexis Gore
Joe Quinlan +44 (0)20 7618 9100
About Kromek Group plc
Kromek Group plc is a technology group (global HQ in County
Durham) and a leading developer of high performance radiation
detection products based on cadmium zinc telluride ("CZT") and
other advanced technologies. Using its core technology platforms,
Kromek designs, develops and produces x-ray and gamma ray imaging
and radiation detection products for the medical, security
screening and nuclear markets.
The Group's products provide high resolution information on
material composition and structure and are used in multiple
applications, ranging from the identification of cancerous tissues
to hazardous materials, such as explosives, and the analysis of
radioactive materials.
The Group's business model provides a vertically integrated
technology offering to customers, from radiation detector materials
to finished products or detectors, including software, electronics
and application specific integrated circuits ("ASICs").
The Group has operations in the UK and US (California and
Pennsylvania), and is selling internationally through a combination
of distributors and direct OEM sales.
Currently, the Group has over one hundred full-time employees
across its global operations. Further information on Kromek Group
is available at www.kromek.com and
https://twitter.com/kromekgroup.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFMESDESSEES
(END) Dow Jones Newswires
October 14, 2020 02:00 ET (06:00 GMT)
Kromek (LSE:KMK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kromek (LSE:KMK)
Historical Stock Chart
From Jul 2023 to Jul 2024